NCCN Guidelines® Insights - Cervical Cancer Screening

These NCCN Guidelines Insights focus on recent recommendations for cervical cancer screening and management of abnormal screening tests. When the NCCN Panel convened to update the NCCN Guidelines for Cervical Cancer Screening, they decided to adopt and endorse guidelines from other organizations to avoid duplication of effort. Therefore, in July 2013, after review and validation of consensus guidelines from the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology, the NCCN Guidelines for Cervical Cancer Screening were discontinued.

Target Audience

This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Inform clinicians of recent changes to cervical cancer screening recommendations and management of abnormal screening test results
  • Describe the rationale behind the recent changes in management for cervical cancer screening
Additional information
Supporters: 

Supported by an independent educational grant from Prometheus Laboratories Inc., and by an education grant from Exelixis, Inc., and by educational grants from Bayer HealthCare, Onyx Pharmaceuticals, Inc., and Algeta US; Genentech; Genomic Health, Inc.; NOVOCURE; and Merck Sharp & Dohme Corp.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
03/10/2014
Course expires: 
03/10/2015
Cost:
$0.00

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing